Carlos López-Jiménez, Medical Oncologist at the Sarcoma Unit of Fundación Jiménez Díaz University Hospital (Madrid) and a PhD candidate in Molecular Biosciences at Universidad Autónoma de Madrid (UAM), shared on LinkedIn:
“SARCOMA Track in ESMO2026
The ESMO 2026 Congress is here! Here are the key sessions on sarcoma to add to your agenda:
Friday, October 23
- 16:15–17:45 | Beyond traditional therapy: The impact of emerging approaches on sarcoma treatment
- Location: Leon Auditorium – Hall 4
Saturday, October 24
- 10:15 – 11:30 | Multidisciplinary insights for effective care in gynaecological sarcomas
Location: Cordoba Auditorium – Hall 4 - 14:45–16:15 | Proffered Paper: Sarcoma
Location: Malaga Auditorium – Hall 3
Sunday, October 25
- 16:30–17:15 | Frontline treatment for leiomyosarcoma: What level of evidence is required for clinical implementation?
- Location: Malaga Auditorium – Hall 3
Monday, October 26
- 08:30–10:00 | Rapid Oral: Sarcoma
Location: Malaga Auditorium – Hall 3 - 12:00–12:45 | Posters: Sarcoma
- 14:45–16:15 | Optimising GIST management: From prognostic insights to new therapeutic strategies
Location: Madrid Auditorium – Hall 4 - 16:30–16:42 | Presidential Symposium III. Risvutatug rezetecan (Ris-Rez) versus gemcitabine and docetaxel (GD) in heavily pretreated patients (pts) with relapsed or refractory (R/R) osteosarcoma: Primary results from the phase 3 ARTEMIS-011 study
Location: Alicante Auditorium – Hall 6
See you at ESMO2026!”
You can also read: 20 Posts Not to Miss from ESMO Congress 2026: Day 1
